Novartis International AG (CH) - Novartis JAK inhibitor provides marked and durable clinical benefits in patients with myelofibrosis, a rare, life-threatening blood cancer - Drugs.com MedNews
Links shared publicly online about this topic.
- 869total visits
Novartis International AG (CH) - Novartis JAK inhibitor provides marked and durable clinical benefits in patients with myelofibrosis, a rare, life-threatening blood cancer - Drugs.com MedNews
Myelofibrosis is a blood cancer characterized by bone marrow failure, enlarged spleen, poor quality of life and shortened survival 1 Phase I II data published i
View full resource at drugs.com
Tags: Cancer, Bone, Drug, Novartis
Most Recently Shared on September 16, 2010 at 8:24 pm By:
Novartis International AG (CH) - Novartis JAK inhibitor provides marked and durable clinical benefits in pati... http://bit.ly/aoiFYC #drug
Advertisement
